GlassScriptPhysician profile
Hamid Sharfuddin Hamdi
NPI 1689645541
$4,578.17
in general payments reported to CMS, 2019-2025
32 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.50 · 2020: $41.24 · 2021: $420 · 2022: $825 · 2023: $1,603 · 2024: $1,129 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,272.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,123.77 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $524.57 | 2019-2025 | |
| Eisai INC. | $321.04 | 2022-2025 | |
| Ucb, INC. | $312.06 | 2022-2025 | Rystiggo, Briviact, Nayzilam |
| Neurocrine Biosciences, INC. | $283.51 | 2022-2024 | Ingrezza, Ongentys |
| Argenx US, INC. | $221.88 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Pfizer INC. | $164.53 | 2023-2025 | |
| Lilly USA, LLC | $155.81 | 2022-2025 | Amyvid, Reyvow, Emgality |
| Acadia Pharmaceuticals INC | $147.08 | 2021-2024 | Nuplazid |
| Sk Life Science, INC. | $134.07 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $128.84 | 2022 | |
| Allergan, INC. | $120.30 | 2020-2022 | |
| Abbott Laboratories | $105.56 | 2024-2025 | Infinity |
| Emd Serono, INC. | $104.91 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $99.80 | 2024-2025 | Ultomiris |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $88.12 | 2022-2024 | Austedo Xr, Ajovy |
| Amgen INC. | $79.08 | 2021-2023 | Aimovig |
| Biogen, INC. | $77.85 | 2021-2025 | Skyclarys |
| Biohaven Pharmaceuticals, INC. | $46.67 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $37.58 | 2022 | |
| Acorda Therapeutics, INC | $36.02 | 2021-2023 | Inbrija, Ampyra |
| Grifols USA, LLC | $32.43 | 2021-2023 | Gamunex-C |
| Impel Pharmaceuticals INC. | $32.41 | 2023 | Trudhesa |
| Csl Behring | $31.24 | 2023 | Hizentra |
| Janssen Biotech, INC. | $25.90 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.65 | 2024 | Hyqvia |
| Otsuka America Pharmaceutical, INC. | $23.14 | 2023 | Rexulti |
| Celgene Corporation | $23.08 | 2022 | |
| Averitas Pharma INC. | $22.48 | 2023 | Qutenza |
| Livanova USA, INC. | $18.73 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Ani Pharmaceuticals, INC. | $16.93 | 2023 | Purified Cortrophin Gel |
| Supernus Pharmaceuticals, INC. | $15.13 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Hamdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.